New two-year data show 39 percent patients treated with CAR T remain in remission
Monday, December 3, 2018 - 11:00
in Health & Medicine
A new article shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy (CAR T) Yescarta® (axicabtagene ciloleucel) remained in remission more than two years (27.1 months median follow up) following therapy, and more than half of the patients treated remain alive.